Project description
A chimeric peptide key to the treatment of Alzheimer's and Parkinson's diseases
Alzheimer’s and Parkinson’s diseases are both neurological illnesses caused by damaged brain cells. In the race to find a cure, clinical trials based on anti-amyloid plaques immunotherapies have been unsuccessful. The EU-funded AmInnovation offered a novel solution – AmyP53, a disruptive innovation that can block the very first step of these diseases. The project aimed to de-risk AmyP53 by evaluating its safety in animals. Through the project, the candidate therapeutic agent was synthesised and characterised for its chemical and biological properties and administered in male and female rats via the intravenous and intranasal routes. As expected, all outcomes were outstanding, demonstrating no single toxicity issue, which definitively does open the door for the first-in-human trials very soon.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- medical and health sciencesbasic medicineneurologyparkinson
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1
Coordinator
13240 Septemes-les-vallons
France
See on map